98%
921
2 minutes
20
Background: To evaluate the prognostic value of preoperative activated partial thromboplastin time (APTT) in patients who underwent coronary artery bypass grafting (CABG).
Methods: All data were extracted from the Medical Information Mart for Intensive Care III (MIMIC-III) database. The study population was divided to two groups according to the optimal cut-off value of APTT calculated by X-tile software, and Cox proportional hazard model was used to define independent effect of APTT on 4-year mortality. Survival curves were estimated by the Kaplan-Meier method, and the area under the receiver-operating characteristic curve (AUC) was calculated to compare APTT with other severity scores. Propensity score matching (PSM) analysis were applied to ensure the robustness of this study.
Results: A total of 2,706 patients were included. The optimal cut-off value of APTT for 4-year mortality was 44 seconds. The Cox proportional hazard model showed that patients with APTT ≥ 44 had a significantly higher risk of all-cause death than those with APTT < 44 both before (HR (95% CI), 1.42 (1.16-1.74), < 0.001) and after PSM (HR (95% CI), 1.47 (1.14-1.89), = 0.003). The survival curves showed that patients with longer APTT had a significantly lower 1-year and 4-year cumulative survival probability. The ROC of APTT combined with other severity scores significantly increased predictive ability for 1-year and 4-year mortality.
Conclusions: A longer APTT (≥44) was associated with a higher risk of mortality and can serve as a prognostic predictor in CABG patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509521 | PMC |
http://dx.doi.org/10.1155/2022/2918654 | DOI Listing |
Background: Data on the levels of rivaroxaban-specific anti-factor Xa activity (AFXaA) within three weeks of starting high-dose rivaroxaban therapy in patients with cancer-associated thromboembolism (CAT) is limited. This study aimed to determine initial levels of rivaroxaban-specific AFXaA in patients with CAT to assist with drug monitoring.
Methods: This study included a total of 33 patients from December 2017 through January 2019.
Int J Lab Hematol
September 2025
MAHSC Professor, The University of Manchester, Manchester, UK.
Background: Coagulation screening, consisting of prothrombin time (PT) and activated partial prothrombin time (aPTT), is routinely performed in paediatrics to identify bleeding disorders or guide peri-procedural management. We evaluated the trends in utilisation and diagnostic yield of PT and aPTT testing as part of coagulation screening in a tertiary paediatric centre.
Methods: All PT and aPTT samples received from June to September 2024 were analysed.
Front Oncol
August 2025
Department of Anesthesiology, Qinghai Provincial People's Hospital, Xining, China.
Objective: To study the application of thrombolysis diagram (TEG) and routine coagulation test in the evaluation of coagulation function in patients with hepatic hydatid.
Methods: The observation group consisted of 69 cases of hydatid liver patients undergoing elective combined segmenectomy, and the control group consisted of 69 healthy subjects. The correlation analysis of TEG, six coagulation items and PLT in the preoperative observation group and control group was conducted.
Front Pediatr
August 2025
Division of Pediatric Intensive Care, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Türkiye.
Objective: Catheter-related thrombosis is a common complication of central venous catheter insertion. As the use of central venous catheters increases in pediatric critical care settings, catheter-related thrombosis is becoming more common among patients who typically have multiple risk factors for thromboembolism. We aimed to investigate impact of catheter-to-vein diameter ratio on thrombosis in pediatric central venous catheterization.
View Article and Find Full Text PDFFood Sci Biotechnol
October 2025
Department of Biotechnology, Yonsei University, Seoul, 03722 Republic of Korea.
Thrombosis is a leading cause of cardiovascular diseases, driven by platelet aggregation, endothelial activation, and vascular occlusion. While L. (onion) is known for its health benefits, the antithrombotic potential of its peel remains underexplored.
View Article and Find Full Text PDF